Correction of lipid metabolism disorders with atorvastatin in combination with UDCA in NAFLD
https://doi.org/10.31146/1682-8658-ecg-181-9-40-44
Abstract
Objective: to evaluate the therapeutic efficacy of the combined use of ursodeoxycholic acid and atorvastatin in non-alcoholic fatty liver disease (NAFLD) with concomitant atherogenic dyslipidemia.
Materials and methods.123 patients with NAFLD at the stage of steatosis were examined, among them 66 women and 57 men aged 30 to 70 years. In verification of NAFLD, an ultrasound examination (ultrasound) of the hepatobiliary system was used using the SONIX OP apparatus (Canada). To exclude fibrosis in the liver parenchyma, sonoelastographywas performed on an AIXPLORER apparatus (France) and the FibroTest and FibroMax tests developed by BioPredictiv (Paris, France) were used. The lipid profile was determined on an analyzer FP-901 (M) from Labsystems (Finland) (Spain, Barcelona). The method of multifractional (5-phase) duodenal sounding (MFDZ) was used, which makes it possible to evaluate bile indices (cholesterol and bile acids).
Results. Ultrasound of the liver and SteatoTest revealed steatosis in all patients with NAFLD. The examined identified signs of atherogenic dyslipidemia. There was a significant increase in cholesterol in portions “B” and “C” of bile (by 79.9% (p = 0.001) and 76.89% (p = 0.001), respectively), a decrease in the amount of bile acids in portions “B” and “ C ”bile (by 46.74% (p = 0.001) and 30.56% (p = 0.1), respectively). A sharp decrease in the cholecholesterol coefficient (by 90.55% (p = 0.001) and 86.03% (p = 0.01), respectively) confirms the high lithogenic properties of bile. The combined use of ursodeoxycholic acid (UDCA), simultaneously with atorvastatin, manifested a more pronounced both lipid-lowering effect and correction of the lithogenic properties of bile, in comparison with UDCA monotherapy.
Conclusion. The effectiveness of the course application of UDCA in combination with atorvastatin in the correction of hyper- and dyslipidemia and biochemical parameters of bile in patients with NAFLD at an early stage of steatosis was determined.
About the Authors
E. V. Suchkova
Federal State Budgetary Educational Institution of Higher Education “Izhevsk State Medical Academy” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Elena V. Suchkova, MD, docent of the department of propaedeutics of internal diseases with a course of nursing
426034, st. Kommunarov, 281, Izhevsk
A. P. Lukashevich
Federal State Budgetary Educational Institution of Higher Education “Izhevsk State Medical Academy” of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Anna P. Lukashevich, candidate of medical sciences, assistant of the department of propaedeutics of internal diseases with a course of nursing
426034, st. Kommunarov, 281, Izhevsk
References
1. Ивашкин В. Т. Распространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования Direg 2. Российский журнал гастроэнтерологии, гепатологии и колопроктологии.2015;25(6):31–41. Ivashkin V. T. Rasprostranennost’ nealkogol’noy zhirovoy bolezni pecheni u patsientov ambulatorno-poliklinicheskoy praktiki v Rossiyskoy Federatsii: rezul’taty issledovaniya Direg 2. [The prevalence of non-alcoholic fatty liver disease in patients with outpatient practice in the Russian Federation: the results of the Direg 2 study]. Rossijskij zhurnal gastroenterologii, gepatologii i koloproktologii, 2015, Vol. 25, no. 6, pp. 31–41.
2. Подымова С. Д. Современный взгляд на патогенез и проблему лечения неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2016,(5):74–82. Podymova SD. The Modern View on Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Eksp Klin Gastroenterol. 2016;(5):74–82.
3. Лазебник Л. Б., Звенигородская Л. А. Метаболиче ский синдром и органы пищеварения. – Москва: Анахарсис, 2009. 184 с. Lazebnik L. B., Zvenigorodskaya L. A. Metabolicheskiy sindrom i organy pishchevareniya. [Metabolic syndrome and digestive organs]. Moscow: Anakharsis, 2009. 184 p.
4. Корочина И. Э. Гастроэнтерологические аспекты метаболического синдрома. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2008;18(1):26–37. Korochina I. E. Gastroenterologicheskie aspekty metabolicheskogo sindroma. [Gastroenterological aspects of the metabolic syndrome]. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2008, Vol.18, no.1, pp.26–37.
5. Мирошниченко В. П., Громашевская Л. Л., Касаткина М. И. и соавт. Определение содержания желчных кислот и холестерина в желчи. Лабораторное дело.1978,(3):149–153. Miroshniche nk o V. P., Grom a she vsk aya L . L ., Kasatkina M. I., et al. Opredelenie soderzhaniya zhelchnyk h kislot i k holesterina v zhelchi. [Determination of bile acids and cholesterol in bile]. Laboratornoe delo.1978, no.3, pp.149–153.
6. Ильченко А. А. Заболевания желчного пузыря и желчных путей. – Москва: Анахарсис, 2006.448 с. Il’chenko A. A. Zabolevaniya zhelchnogo puzyrya i zhelchnykh putey. [Diseases of the gallbladder and biliary tract]. Moscow, Anakharsis, 2006. 448 p.
7. Бритов А. Н. Биохимический, структурный и клинический анализ плейотропных эффектов статинов. Кардиоваскулярная теория и профилактика. 2009,(5):92–102. Britov A. N., Gomazkov O. A. Biochemical, structural and clinical analysis of statins’ pleiotropic effects. Cardiovascular Therapy and Prevention. 2009;8(5):92– 102. (In Russ.)
Review
For citations:
Suchkova E.V., Lukashevich A.P. Correction of lipid metabolism disorders with atorvastatin in combination with UDCA in NAFLD. Experimental and Clinical Gastroenterology. 2020;(9):40-44. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-181-9-40-44
Views:
397
Email this article 